Ep. 78 Surgery for High Risk Prostate Cancer with Dr. David Penson episode artwork

EPISODE · Feb 1, 2023 · 50 MIN

Ep. 78 Surgery for High Risk Prostate Cancer with Dr. David Penson

from BackTable Urology · host BackTable

In this episode of BackTable Urology, Dr. Aditya Bagrodia interviews Dr. David Penson, professor and chair of urologic oncology at Vanderbilt University, about the indications and benefits of surgery for high risk prostate cancer. --- SHOW NOTES First, Dr. David Penson gives the traditional definition of high-risk prostate cancer, which is a PSA level over 20 ng/mL, a Gleason grade greater than 10, and a cancer staged at T2 or higher. However, he notes that in recent years, a more heterogeneous criteria has developed, so some patients with a Gleason grade greater than 8 and a T3 stage can also be considered high risk. Dr. Penson believes that pathological analysis is the best criteria to use when assessing risk and also uses MRI to distinguish between T2 and T3 patients and look for the median lobe before surgery. In his personal experience, he has noted that some patients will find online information about prostate cancer as a relatively benign chronic disease. For patients with high risk cancer, it is important to emphasize that the conventional active surveillance approach for low risk prostate cancer will not be beneficial. Both doctors agree that sending their patients curated, quality information is important and recommend using the WellPrept app. The doctors also discuss different imaging modalities involved in staging, such as PSMA PET scan, a bone scan, and prostate MRI. Before surgery, patients may receive neoadjuvant treatment. In the past, GnRH agonists were used, but long term data showed that patients receiving this type of therapy in addition to surgery had the same recurrence rate as patients who underwent surgery alone. Recently, newer neoadjuvant treatments, like PARP inhibitors, have been developed. Next, Dr. Penson speaks about choosing surgery versus radiation therapy (RT) as a primary treatment. The main risk of prostatectomy is its impact on continence and sexual dysfunction. The downside of radiation therapy is that the possibility of surgery as a therapeutic option is eliminated and its side effects, such as irritating urinary symptoms. Dr. Penson also notes that nerve sparing prostatectomies may be cancer sparing. In his opinion, if patients have impotence at baseline, nerve sparing surgery is not beneficial because of the risk of leaving positive margins. Contraindications to surgery include rectal involvement, a history of multiple abdominal surgeries, severe heart disease, bladder neck involvement, and a high volume nodal disease. Ideal prostatectomy patients are ones who have high grade disease contained in the prostate (T2) and patients with preexisting lower urinary tract symptoms (LUTS). Finally, the doctors discuss the use of nomograms to determine the extent of cancer control and the need for additional therapy. Dr. Penson has limited use for nomograms. He believes that they can generally be used to predict mortality, but not cure rates. He prefers to base prognosis on postoperative results. If the postoperative pathology report comes back with widely positive margins or bladder neck involvement, he discusses RT as an adjuvant treatment with his patients. For this reason, he emphasizes the need for collaboration with radiation oncologists and multidisciplinary tumor boards. --- RESOURCES WellPrept App: https://wellprept.com/

Episode metadata supplied by the publisher feed · Published Feb 1, 2023

Embed this episode

NOW PLAYING

Ep. 78 Surgery for High Risk Prostate Cancer with Dr. David Penson

0:00 50:27

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

GU Cast | Urology Podcast Professor Declan Murphy & Dr Renu Eapen A urology podcast, focussing on prostate cancer, kidney cancer, bladder cancer, testis and penile cancer. Join Professor Declan Murphy and Dr Renu Eapen from Peter MacCallum Cancer Centre in Melbourne for this regular dive into the world of genitourinary (GU) Oncology and Urology. Regular guests from all over the world, from every walk of life. Find out more gucast.org  EAU Podcasts European Association of Urology This is the official podcast channel of the European Association of Urology and the European School of Urology. The EAU Podcast is your source for the latest information across the full urological spectrum. Take your clinical practice to new heights and tune in! European Urology Podcast Declan Murphy & European Urology Family  A monthly podcast brought to you by European Urology, the world's top ranked urology journal. Featuring highlights from our latest edition, including interviews with authors and editors, and lots of other entertaining urology stuff. Co-hosted by European Urology Digital Editor, Professor Declan Murphy, and Dr Nikita Bhatt, Urology Fellow, Newcastle, UKAlso posts as a full video podcast on our YouTube channel https://www.youtube.com/@EuropeanUrologyTVBrought to you by the team behind GU Cast.  Urology Care Podcast Urology Care Foundation The Urology Care Foundation is the official foundation of the American Urological Association. We support reliable patient education on urology health issues. Learn more at UrologyHealth.org.

Frequently Asked Questions

How long is this episode of BackTable Urology?

This episode is 50 minutes long.

When was this BackTable Urology episode published?

This episode was published on February 1, 2023.

Can I download this BackTable Urology episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!